Press Room

PhRMApedia Press Room

PhRMApedia's Press Room will provide the most recent press releases. Search PhRMApedia for additional press releases.  PhRMApedia is your new resource hub. You can search our entire database of media releases, reports, white papers, videos and more. Type your keywords in the search bar and explore PhRMA’s resources. Search results will appear by type, title and date. 

PhRMA Names Ieva M. Augustums as Deputy Vice President, Communications and Public Affairs

Washington, DC – The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today that Ieva M. Augstums will join the organization as Deputy Vice President of Communications and Public Affairs, effective October 1, 2014.

Read more.


Patient Advocates, Researchers Honored at 2014 Research & Hope Awards

Washington, D.C. (September 11, 2014) — The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced the recipients of the 2014 Research & Hope Awards, honoring researchers and patient advocates for their role in advancing biopharmaceutical research and improving patients’ access to care. This year’s awardees were recognized for their role in the fight against HIV/AIDS, a devastating disease that has taken the lives of more than 36 million people worldwide.

Read more.


New Medicines in Development Give Hope to Patients with HIV/AIDS

Washington, D.C. (September 10, 2014) — America’s biopharmaceutical research companies are currently developing 44 medicines and vaccines for HIV/AIDS treatment and prevention, according to the latest Medicines in Development report by the Pharmaceutical Research and Manufacturers of America (PhRMA). A second report, a PhRMA-sponsored white paper by Boston Healthcare Associates, Inc. (BHA), “The Value of Innovation in HIV/AIDS Therapy ” highlights the progress in HIV/AIDS treatment and its impact on patients afflicted with the disease. 

Read more.


PhRMA Statement on Open Payments Data Concerns

Washington, D.C. (August 26, 2014) — Pharmaceutical Research and Manufacturers of America (PhRMA) Assistant General Counsel, John Murphy, issued the following statement regarding the announcement by the Centers for Medicare and Medicaid Services (CMS) to delay publication of a significant portion of data in the open payments database – a database established through the Physician Payments Sunshine Act included in the Affordable Care Act.

Read more.


Survey Shows Americans Remain Positive About Their Own Health, Less Optimistic About ‘Average American’

Washington, D.C. (August 13, 2014)  The majority of Americans report they have had a good year when it comes to their personal health and are paying more attention to their health compared to just a few years ago, according to From Hope to Cures: PhRMA’s Second Annual National Health Survey.

Read more.


Nearly 100 New Medicines in Development for Arthritis

Washington, D.C. (July 24, 2014) — America’s biopharmaceutical research companies are developing 92 innovative new medicines to help the millions of Americans affected by arthritis, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). These medicines in development – all either in clinical trials or under review by the U.S. Food and Drug Administration – include 55 for rheumatoid arthritis, 15 for musculoskeletal pain, 10 for osteoarthritis and 7 for psoriatic arthritis.

Read more.


PhRMA Statement on Medicare Rights Center and Social Security Works Medicare Paper

Washington, D.C. (July 23, 2014) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President, Communications, Robert Zirkelbach issued the following statement: “Finding viable solutions to contain Medicare costs is critically important, but imposing price controls in Medicare would hurt the millions of seniors who rely on the Part D program to access the medicines they need. These policies would fundamentally alter the competitive nature of the program that has led to its success and could increase beneficiary premiums, cause job loss, and reduce incentives for innovation."

Read more.


UK Cancer Patients Face Increasing Coverage Restrictions Due to Centralized Cost-Effectiveness Standard, New Report Shows

Washington, D.C. (July 10, 2014)New research results announced today quantify the extent to which centralized value assessments by the UK’s National Institute for Health and Care Excellence (NICE) lead to coverage denials and patient access restrictions to new drugs and biologics. The analysis conducted by Context Matters, and sponsored by the Pharmaceutical Research and Manufacturers of America (PhRMA), shows that use of centralized cost-effectiveness standards by NICE and similar appraisals in other countries limit patients’ access to new cancer treatments, which evolve rapidly and are increasingly personalized.

Read more.


Global Biopharmaceutical Industry Signs New Policy Partnership Agreement with Government of Algeria To Develop Innovative Medicines Sector

San Diego (25 June 2014)—Representative of the Pharmaceutical Research and Manufacturers of America (PhRMA) have signed a Memorandum of Understanding (MOU) with theNational Pharmaceutical Products Control Laboratory of Algeria, setting out a new framework for partnership on policies to encourage more innovation, employment and investment in this strategic sector in the Algerian economy, PhRMA announced here today.   

Read more. 


Charles River Associates Releases Updated HTA Comparison Reports

Washington, D.C., Brussels (June 17, 2014) — Charles River Associates today announced the release of a report at the HTAi Annual Meeting titled “A Comparative Analysis of the Role and Impact of Health Technology Assessment.” The report, commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA), updates a previous study conducted in 2011.  

Read more. 


New Medicines in Development for Top Chronic Diseases Affecting Older Americans

Washington, D.C. (June 16, 2014) — America’s biopharmaceutical research companies are developing 435 innovative new medicines to target 15 leading chronic conditions affecting the Medicare population, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). These medicines in development – all either in clinical trials or under review by the Food and Drug Administration (FDA) –are diverse in scope.

Read more. 


New Report: Many Exchange Plans Burden the Most Vulnerable Patients with High Out-of-Pocket Costs for Vital Medicines

Washington, D.C. (June 11, 2014) — A new report demonstrates that the majority of plans in the Health Insurance Exchanges are placing a significant out-of-pocket burden on patients with serious illnesses by requiring particularly high cost-sharing for all medicines used to treat certain conditions. This analysis by Avalere Health finds that the vast majority of plans in the Health Insurance Exchanges require relatively high cost sharing for all medicines in at least one class. This cost burden leaves many patients with nowhere to turn and can negatively affect patients’ health, and even their lives, by limiting access to needed care.

Read more. 


PhRMA Statement on FDA Draft Guidance on Labeling for Products Approved Under the Accelerated Approval Pathway

Washington, D.C. (May 30, 2014) — Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President of Scientific and Regulatory Affairs Sascha Haverfield, PhD, issued the following statement on the Food and Drug Administration (FDA) draft guidance on labelling for human prescription drug and biologics approved under the Accelerated Approval pathway.

Read more. 


Castellani Statement on Prescription Drug Costs

Washington, D.C. (May 29, 2014) – The Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani today released the following statement on the cost and value of medicines: “It is penny wise and pound foolish to focus solely on the price of a new medicine while completely ignoring the value it provides to patients and the health care system broadly. 

Read more. 


PhRMA Statement on Withdrawal of Patent Legislation from Senate Judiciary Committee Agenda

Washington, D.C. (May 21, 2014) — Pharmaceutical Research and Manufacturers of America (PhRMA) Executive Vice President and General Counsel Mit Spears issued the following statement on the patent legislation pending in the U.S. Senate: "PhRMA appreciates the efforts of Senate Judiciary Committee Chairman Patrick Leahy (D-VT) to achieve consensus on patent legislation and for recognizing that an overly broad bill could harm innovative companies and universities that depend on strong intellectual property protection.

Read more. 


New Report: Many Patients with Exchange Coverage to Pay More than Twice As Much Out Of Pocket for Prescriptions Compared to Employer Plans

Washington, D.C. (May 15, 2014) — WASHINGTON, D.C. (May 15, 2014) — A new report by Milliman, Inc. finds that Silver plans with combined deductibles offered through the Health Insurance Exchanges may require patients to pay more than twice as much out of pocket for prescription medicines overall as they would under a typical employer plan. This is a far larger increase in out-of-pocket costs than was found for other medical care.

Read more. 


More than 100 New Medicines in Development to Treat Mental and Addictive Disorders

Washington, D.C. (May 5, 2014) — America’s biopharmaceutical research companies currently are developing 119 novel new medicines to help improve the lives of the estimated 61.5 million Americans that are affected by mental health disorders, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Read more. 


PhRMA Statement on 2014 Special 301 Report

Washington, D.C. (April 30, 2014) – Maintaining global incentives for research and development into new medicines is essential for continued innovation of treatments for improving the health and lives of patients. Worldwide respect for intellectual property helps to ensure that patients around the globe receive the benefits of future discoveries of life-saving medicines, including the more than 5,400 medicines currently in development by the pharmaceutical industry.

Read more. 


IMS Health Report Finds Medicines Helping Bend the Health Care Cost Curve

Washington, D.C. (April 15, 2014) – The Pharmaceutical Research and Manufacturers of America (PhRMA) Executive Vice President Josephine Martin released the following statement today: “Growth in medicine spending remains at historically low levels and continues to contribute to the bending of the healthcare cost curve, according to a new IMS Health report on prescription drug spending."

Read more. 


Pfizer’s Ian Read Becomes PhRMA Board Chairman; Ken Frazier, George Scangos Assume New Posts

Washington, D.C. (April 11, 2014) — Ian C. Read, chairman and CEO of Pfizer, Inc, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) today at the trade association’s annual meeting. Also elected were Kenneth C. Frazier, chairman, president and CEO of Merck & Co, Inc., as chairman-elect of the PhRMA Board of Directors, and George A. Scangos, Ph.D., CEO of Biogen Idec, as Board treasurer.

Read more. 


New Report Reveals Growth Trajectories and Top Policy Factors Affecting Biopharmaceutical Innovation & Growth

Washington, D.C. (April 10, 2014) – Today the Pharmaceutical Research and Manufacturers of America (PhRMA) released a report that outlines two potential growth trajectories for the U.S. biopharmaceutical sector and the top policy factors that enable the industry to innovate and, in turn, contribute to the U.S. economy. 

Read more. 


PhRMA Statement on AIR340B Analysis

WASHINGTON, D.C. (March 25, 2014) – Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani issued the following statement today: “As a member of the Alliance for Integrity and Reform of 340B (AIR340B), PhRMA recognizes the value and importance of the 340B program and is committed to ensuring the program fulfills its promise to vulnerable and uninsured patients. A new AIR340B report, “Unfulfilled Expectations: An analysis of charity care provided by 340B Hospitals,” provides further evidence that the program is in urgent need of expanded Congressional and administrative oversight and reform."

Read more. 


Nearly 40 New Medicines in Development for Parkinson’s Disease

Washington, D.C. (March 24, 2014) – America’s biopharmaceutical research companies currently are developing 37 innovative new medicines to help the estimated 10 million people worldwide who are living with Parkinson’s disease. These medicines in development – all either in clinical trials or under review by the Food and Drug Administration (FDA) – include 23 for Parkinson’s disease, 11 for related conditions and 3 diagnostics, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). 

Read more.


I'm In Campaign to Educate Underrepresented Populations About Clinical Trial Participation

Washington, D.C. (March 12, 2014) – The Pharmaceutical Research and Manufacturers of America (PhRMA) and the National Minority Quality Forum today announced a first-of-its-kind national campaign to help increase diversity in clinical trials.

Read more.


New Report Shows Clinical Trials in Piedmont Triad Region Benefit Local Patients, Economy and Medical Science 

WINSTON-SALEM, NC (March 10, 2014) –  Working with institutions in Winston-Salem, Greensboro, High Point and Burlington, the nation’s biopharmaceutical research companies have conducted over 2,000 clinical trials of new medicines in the 12-county Piedmont Triad since 1999, says a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Read more.


PhRMA's Statement on President's 2015 Budget

Washington, DC (March 4, 2014) – “President Obama claims his budget invests in innovation and allows America to compete in the 21st century economy, when the reality is that his proposals undermine such efforts. This budget is damaging to patients, innovation, and our economy."

Read more.


Chuck Clapton joins PhRMA as SVP of Federal Advocacy

Washington, DC (February 25, 2014) – The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today the appointment of Charles “Chuck” Clapton to the position of Senior Vice President, Federal Advocacy, effective March 17, 2014. 

Read more. 


PhRMA Statement on Proposed Rule on Medicare Advantage & Part D 

WASHINGTON, D.C. (February 19, 2014) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement: “PhRMA opposes the proposed rule on Medicare Advantage and Part D that CMS released in early January because it could disrupt care for millions of beneficiaries.

Read more. 


Nearly 200 New Medicines in Development for Diabetes

WASHINGTON, D.C. (February 11, 2014) – America’s biopharmaceutical research companies currently are developing 180 innovative new medicines to help the nearly 400 million people who have diabetes worldwide. These medicines in development – all either in clinical trials or under review by the Food and Drug Administration (FDA) – include 30 for type 1 diabetes, 100 for type 2 and 52 for diabetes-related conditions, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Read more. 


PhRMA Joins Accelerating Medicines Partnership to Advance Discovery and Development of New Treatments

WASHINGTON, D.C. (February 4, 2014) – The Pharmaceutical Research and Manufacturers of America (PhRMA) has joined the National Institutes of Health (NIH), 10 biopharmaceutical companies and several non-profit disease foundations in a partnership to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets of disease.

Read more. 


PhRMA Statement on State of the Union Address

WASHINGTON, D.C. (January 29, 2014) – Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani issued the following statement: "President Obama’s address comes at a time when America’s biopharmaceutical research companies are bringing pioneering new medicines to patients, supporting high-value American jobs and helping strengthen local communities and our national economy. Continued progress – the kind that President Obama urged for last night – is only possible, however, if we fully embrace innovation. 

Read more. 


Biopharmaceutical Sector Stepping Up to Improve STEM Education in U.S. New Battelle Report

WASHINGTON, D.C. (January 22, 2014) – Innovative biopharmaceutical companies and their corporate foundations are making significant contributions to U.S. science, technology, engineering and math (STEM) education through a broad range of local, state and national level programs and initiatives aimed at elementary through post-secondary education, according to a first-of-its-kind report by the Battelle Technology Partnership Practice. 

Read more. 


PhRMA Statement on Release of Sequestered FY2013 PDUFA Fees in Omnibus Spending Package

WASHINGTON, D.C. (January 14, 2014) – Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President of Scientific and Regulatory Affairs Sascha Haverfield, PhD, issued the following statement on the release of sequestered prescription drug user fees included in the omnibus spending package filed yesterday.

Read more. 


New Report Shows Iowa Clinical Trials Benefit State's Patients, Economy and Science

DES MOINES, IA (January 9, 2014) – Working with Iowa research institutions, including the members of the new Iowa Coalition of Clinical Researchers (ICCR), the nation’s biopharmaceutical research companies have conducted 1,287 clinical trials of new medicines in the state since 1999, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). 

Read more. 


Data Sharing Commitments Enhance Research and Scientific Knowledge, Advance Patient Care and Improve Public Health

Brussels and Washington, D.C (January 1, 2014) — The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) are pleased to announce that implementation of the joint Principles for Responsible Clinical Trial Data Sharing begins today.

Read more. 


PhRMA Statement on India and Intellectual Property 

Washington, D.C. (December 30, 2013) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matt Bennett provided the following statement:

“Innovation is critical to meeting patients’ unmet medical needs and is particularly relevant in the context of evolving healthcare systems around the world. Today’s New York Times article about India’s anti-innovation intellectual property policies looks at complex questions through the too-simple lens of cost."

Read more. 

 


New Report Shows Minnesota Clinical Trials Benefit Patients, State Economy and Science

MINNEAPOLIS, MN (December 13, 2013) – Working with Minnesota research institutions, including the members of the Minnesota Clinical Research Alliance (MCRA), the nation's biopharmaceutical research companies have conducted 2,945 clinical trials of new medicines since 1999, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).  This total reflects an increase of about 300 trials over the last year.

Read more. 


Panel Discussion and New Report Highlight Benefit of Vermont Clinical Trials for Patients, State Economy

BURLINGTON, VT. (December 12, 2013) – Working with Vermont research institutions, including the University of Vermont and Fletcher Allen Health Care in Burlington, the nation's biopharmaceutical research companies have conducted 566 clinical trials of new medicines since 1999, according to a new report released today and highlighted at a panel discussion in Burlington. According to the latest data from 2011, this activity also generated $267 million per year in economic activity in the state.

Read more. 


PhRMA Statement on House Passage of the Innovation Act 

Washington, D.C. (December 5, 2013) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matt Bennett issued the following statement on H.R. 3309, the Innovation Act, as passed by the U.S. House of Representatives today:  “PhRMA commends the House of Representatives for its work to curb abusive patent litigation."

Read more. 


Alabama Clinical Trials Benefit Patients and the Economy

BIRMINGHAM, AL (December 4, 2013) – Working with Alabama research institutions, including several facilities in Birmingham, the nation’s biopharmaceutical research companies have conducted 3,431 clinical trials of new medicines in the state over the last 14 years, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).  

Read more. 


Nearly 400 Novel Medicines in Development for Infectious Diseases 

WASHINGTON, D.C. (December 2, 2013) – America’s biopharmaceutical research companies are developing 394 new medicines for infectious diseases, including viral infections, bacterial infections, fungal infections and parasitic infections, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA). 

Read more. 


Drug Quality and Security Act Passes Senate

Washington, D.C. (November 18, 2013) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J Castellani issued the following statement: “PhRMA is pleased that the Senate has passed the Drug Quality and Security Act and that the bill will now head to the White House for President Obama’s signature." 

Read more. 


4,710 Clinical Trials Conducted By Massachusetts Research Centers  Total Includes 491 Trials Conducted In Worcester Since 1999  

Worcester, MA (November 12, 2013) – Working with Massachusetts research institutions, including several facilities in Worcester, the nation’s biopharmaceutical research companies have conducted 4,710 clinical trials of new medicines in the state over the last 14 years, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). The report, “Research in Your Backyard:  Pharmaceutical Clinical Trials in Massachusetts,” shows biopharmaceutical companies continuing to expand clinical research with over 700 trials added throughout the state in the last 1.5 years.   

Read more. 


Genetic Alliance & PhRMA Announce Pilot Initiative to Advance Patient-Focused Drug Development

Washington, D.C. (November 4, 2013) — Today, Genetic Alliance and the Pharmaceutical Research and Manufacturers of America (PhRMA) announced an initiative to explore the use of a technology-enabled, crowd-sourcing approach to patient engagement as a complement to ongoing patient-focused drug development efforts under the Prescription Drug User Fee Act (PDUFA V).

Read more. 


PhRMA Statement on FDA's Announcement on Use of SI Units in Regulatory Submissions

Washington, D.C. (October 31, 2013) — Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President of Scientific and Regulatory Affairs Sascha Haverfield, PhD, issued the following statement on the recent announcement by the Food and Drug Administration (FDA) regarding the use of Systeme International (SI) units in regulatory submissions.

Read more. 


Nearly 2,000 Clinical Trials of New Medicines Conducted by Nebraska Research Institutions Since 1999

OMAHA, NEBRASKA (October 28, 2013) -- Working in collaboration with Nebraska clinicians and research institutions, America's biopharmaceutical research companies have conducted 1,937 clinical trials of new medicines in Nebraska over the last 14 years, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). 

Read more. 


PhRMA Statement in Response to New York Times Article

Washington, D.C. (October 14, 2013) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani issued the following statement today:

Elizabeth Rosenthal’s New York Times article, “The Soaring Cost of a Simple Breath,” selectively reports facts, misrepresents the role of medicines in health care and fails to identify the underlying challenges facing patients with asthma and other chronic conditions. The need to improve patient access to life saving medicines is worthy of serious dialogue, but the article’s obvious bias obscures important facts rather than contributing to that important conversation.

Read more. 


Alzheimer's: The Puzzle, The Partners, The Path Forward

WASHINGTON, DC (September 23, 2013) – Please join the Pharmaceutical Research and Manufacturers of America (PhRMA), the Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation at an October 23, 2013 forum focused on the primary hurdles to combating Alzheimer’s Disease (AD), a debilitating neurodegenerative disease that currently afflicts more than 5 million people in the U.S. 

Read more. 


Alzheimer's: The Puzzle, The Partners, The Path Forward

WASHINGTON, DC (September 23, 2013) – Please join the Pharmaceutical Research and Manufacturers of America (PhRMA), the Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation at an October 23, 2013 forum focused on the primary hurdles to combating Alzheimer’s Disease (AD), a debilitating neurodegenerative disease that currently afflicts more than 5 million people in the U.S.

Read more. 


New Report Shows More Than 7,800 Clinical Trials of Medicines  Conducted by Florida Research Institutions Since 1999

WASHINGTON, D.C. (September 16, 2013) – Working in collaboration with Florida clinicians and research institutions, America’s biopharmaceutical research companies have conducted more than 7,800 clinical trials of new medicines in Florida over the last 14 years, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). 

Read more. 


New Report Shows Over 800 Clinical Trials of Medicines  Conducted by Montana Research Institutions Since 1999

WASHINGTON, D.C. (September 13, 2013) –  Working in collaboration with Montana clinicians and research institutions, America’s biopharmaceutical research companies have conducted more than 800 clinical trials of potential new medicines in Montana over the last 14 years, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). 

Read more. 


PhRMA Honors Vaccines Pioneers with Research & Hope Awards

Washington, D.C. (September 11, 2013) — The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today the recipients of the 2013 Research & Hope Awards, honoring outstanding achievements in vaccines research and immunization by individuals and research teams in the biopharmaceutical sector, academic/public research and health care provider communities. “Over the last century, vaccines have transformed the public health landscape in the United States and around the world, preventing disease and improving the quality of life for multiple generations,” said PhRMA President and CEO John J. Castellani. “PhRMA is proud to honor the recipients of this year’s Research & Hope Awards. These inspiring collaborators within the biopharmaceutical ecosystem have helped drive the latest advances in vaccines and immunization to the benefit of patients everywhere.”

Read more. 


More Than 270 Vaccines in Biopharmaceutical Pipeline Offer Hope to Prevent/Treat Wide Array of Diseases

WASHINGTON, D.C. (September 11, 2013) – America’s biopharmaceutical companies are currently developing 271 vaccines to prevent – and in some cases treat – a variety of conditions, including infectious diseases, various forms of cancer and neurological disorders, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). The report is being released in conjunction with PhRMA’s 2013 Research and Hope Awards, which are honoring outstanding achievements in vaccine research and immunization by individuals and organizations in the medical innovation ecosystem. 

Read more. 


New Report Unveils Health, Economic Impact of Clinical Trials in South Carolina

Charleston, SC (August 27, 2013) – The Medical University of South Carolina (MUSC) this morning hosted “Research in Your Backyard,” a press conference announcing the key findings of a new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) that focuses on  clinical trials being conducted by biopharmaceutical research companies and local research collaborators throughout South Carolina. Rep. James Clyburn was a featured speaker at the conference, which took place inside the Drug Discovery Building of the James E. Clyburn Research Center.

Read more.


PhRMA Launches Annual Exploration of America's Health Views, Concerns and Progress

WASHINGTON, D.C. (August 2, 2013) – A new survey commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA) shows 86 percent of Americans believe developing cures for more forms of cancer should be one of the top national health priorities, followed by developing effective treatments for heart disease (78 percent) and more intensive medical care for seniors (76 percent). These findings are the result of a new annual “From Hope to Cures” survey, which explores Americans’ attitudes on personal health and medical concerns.

Read more.


Biopharmaceutical and Medical Device Associations Strongly Support Senate Bill to Exempt FDA User Fees from Sequestration

Washington, DC – August 1, 2013 – Today, Sen. Mark Pryor (D-AR), chairman of the Senate Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration and Related Agencies, and Sens. Roy Blunt, (R-MO), Daniel Coats (R-IN), Al Franken (D-MN), and Jerry Moran (R-KS) introduced S. 1413 to exempt future Food and Drug Administration (FDA) user fees from sequestration.  A similar bill, H.R. 2725, was introduced in the U.S. House of Representatives earlier this month by Representatives Leonard Lance (R-NJ), Anna Eshoo (D-CA), Mike Rogers (R-MI) and Doris Matsui (D-CA).

Read more.


Statement on Physician Payments Sunshine Act

WASHINGTON, D.C. (July 31, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today:

“PhRMA is committed to the principles of the Sunshine Act and continues to believe that careful implementation is essential to ensuring that Sunshine fulfills its objective of usable, transparent, and understandable sharing of information.

Read more.


EFPIA and PhRMA Release Joint Principles for Responsible Clinical Trial Data Sharing to Benefit Patients

Washington, D.C. and Brussels (July 24, 2013) — The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) today strengthened their long-standing commitment to enhancing public health by endorsing joint “Principles for Responsible Clinical Trial Data Sharing: Our Commitment to Patients and Researchers.” “Companies routinely publish their clinical research, collaborate with academic researchers, and share clinical trial information on public websites,” said Christopher Viehbacher, President of EFPIA and CEO of Sanofi. 

Read more.


PhRMA Endorses FDA Safety Over Sequestration Act 

WASHINGTON, D.C. (July 22, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President of Scientific and Regulatory Affairs Sascha Haverfield, PhD, issued the following statement today on ongoing efforts in Congress to resolve the sequestration of prescription drug user fees: “PhRMA remains deeply concerned about the impact of sequestration on the Food and Drug Administration’s (FDA) ability to fulfill its critical public health mission by fostering timely patient access to safe and effective new medicines and advancing regulatory science." 

Read more. 


New Research Highlights “Rare Opportunity” to Improve Health Outcomes, Affordability through Targeted Medication Adherence Efforts 

WASHINGTON, D.C. (July, 8, 2013) – Amid mounting evidence of the negative clinical and economic consequences of medication non-adherence, research featured on the cover of this month’s Health Affairs breaks new ground by urging innovative approaches to improve medication adherence and to “achieve a higher-performing health system.”

Read more. 


PhRMA Statement on New Strategic Plan from the IP Enforcement Coordinator

WASHINGTON, D.C. (June 19, 2013) – Pharmaceutical Research and Manufacturers of America International Senior Vice President Rod Hunter issued the following statement today on the release of the second Joint Strategic Plan from the Intellectual Property Enforcement Coordinator (IPEC) Victoria Espinel:

“While intellectual property infringement threatens the ideas and innovations that are the lifeblood of pharmaceutical companies and, in turn, our industry’s contribution to the U.S. economy, it also presents a very real public health and safety danger to patients world-wide.

Read more.


PhRMA Joins with National Minority Quality Forum and Microsoft to Address Diversity in Clinical Trials

WASHINGTON, D.C. (June 18, 2013) – The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today that it is partnering with the National Minority Quality Forum (NMQF) and Microsoft to help increase diversity in clinical trials.

“Promoting awareness and creating connectivity that can translate into enhanced participation in clinical trials by a diverse patient population is a priority for PhRMA and our member companies,” stated Dr. Salvatore Alesci, M.D., Ph.D, Vice President of Scientific Affairs at PhRMA.  “This collaboration brings clinical research and healthcare closer to each other to prevent disparities in the evaluation and access to innovative medicines.”

Read more. 


PhRMA Statement on Supreme Court Ruling in Patent Settlement Case

WASHINGTON, D.C. (June 17, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Executive Vice President and General Counsel Mit Spears issued the following statement on the decision issued today by the U.S. Supreme Court in the case of Federal Trade Commission v. Actavis, Inc.:

“We are pleased that the Court unanimously rejected the FTC’s position that patent settlement agreements between innovator and generic pharmaceutical companies should be viewed as presumptively unlawful under the antitrust laws."

Read more.


More Than 200 Innovative Medicines in Development For Heart Disease and Stroke

WASHINGTON, D.C. (June 12, 2013) – America’s biopharmaceutical research companies are developing 215 medicines for two of the leading causes of death of Americans – heart disease and stroke, according to a new report and overview released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Every 39 seconds an American dies from cardiovascular disease, and more than 83 million Americans have at least one type of the disease, the American Heart Association (AHA) reports.

Read more. 


PhRMA Statement on Sequestration of PDUFA User Fees

WASHINGTON, D.C. (June 7, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President of Scientific and Regulatory Affairs Sascha Haverfield, Ph.D., issued the following statement today:

“PhRMA remains deeply concerned about the impact of sequestration on the Food and Drug Administration’s (FDA) ability to fulfill its critical public health mission by fostering timely patient access to safe and effective new medicines. 

Read more. 


New Report Shows Over 3,200 Clinical Trials of Medicines Conducted by Indiana Research Institutions Since 1999

WASHINGTON, D.C. (June 4, 2013) –  Working in collaboration with Indiana clinicians and research institutions, America’s biopharmaceutical research companies have conducted 3,266 clinical trials of new medicines in Indiana over the last 13 years, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).  

Read more


Dr. William Chin to Lead PhRMA Science & Regulatory Affairs 

WASHINGTON, D.C. (June 3, 2013) –  The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced that Dr. William Chin will become Executive Vice President of Science and Regulatory Affairs, effective July 1, 2013. Dr. Chin will report to PhRMA President and CEO John J. Castellani and serve as a member of the PhRMA Management Committee. 

Read more. 


Innovative Oncology Medicines Have Led to Impressive Gains in Patient Survivorship

WASHINGTON, D.C. (May 31, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani released the following statement highlighting the value of innovative cancer medicines for patients, the economy and the U.S. health care system:

“As leaders in the oncology community convene at the 2013 Association of Clinical Oncology meeting to share the latest developments in cancer research, it is important to put into context the invaluable contributions that biopharmaceutical companies have made in the fight against these terrible diseases."

Read more


With Active or Extremely Active Hurricane Season Predicted, Rx Response Urges Pre-Disaster Planning Around Medication Needs

Washington, D.C. ( May 30, 2013) – With the federal government’s Climate Prediction Center warning of an active or extremely active 2013 Atlantic hurricane season, Rx Response officials said today that its two key programs that help citizens and communities recover from the impact of hurricanes - Rx Open and Rx on the Run - were ready for action. 

Read more. 


Lori Reilly to Lead PhRMA Policy & Research Department

WASHINGTON, D.C. (May 21, 2013) –  The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced that Lori Reilly will become Executive Vice President of Policy and Research, effective June 7, 2013. She succeeds Rick Smith, who will retire after 11 years of service with PhRMA. Reilly will report directly to PhRMA President and CEO John Castellani and serve as a member of the PhRMA Management Committee. 

Read more. 


RxOpen Activated to Report on Status of Pharmacies in Oklahoma

WASHINGTON, D.C. (May 20, 2013) – Rx Response  elevated its status to Alert and has activated Rx Open in the aftermath of yesterday’s deadly tornado in Moore, Oklahoma. (www.RxResponse.org).  Rx Response and Rx Open are initiatives of America’s bio-pharmaceutical supply system to help ensure the continued flow of medicine to patients in a severe public health emergency,

Read more. 


PhRMA Statement on FDA Benefit Risk Assessment Plan 

WASHINGTON, D.C. (May 9, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President of Scientific and Regulatory Affairs Sascha Haverfield, Ph.D., issued the following statement today on the Food and Drug Administration’s (FDA) Draft PDUFA V Implementation Plan: Structured Approach to Benefit-Risk Assessment in Drug Regulatory Decision Making. 

Read more. 


PhRMA Statement on 2013 Special 301 Report 

WASHINGTON, D.C. (May 1, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) International Vice President Jay Taylor issued the following statement today: 

Maintaining global incentives for research and development into new medicines is essential for continued innovation of treatments for improving the health and lives of patients.

Read more


PhRMA Statement on Decision of the European General Court on EMA Disclosure of Company Data 

WASHINGTON, D.C. (April 30, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matt Bennett issued the following statement today: “The biopharmaceutical industry is firmly committed to enhancing the public health through responsible reporting and publication of clinical research and safety information." 

Read more


Team PhRMA Raises $100,000 for Leukemia/Lymphoma Research

WASHINGTON, D.C. (April 26, 2013) – The Pharmaceutical Research and Manufacturers of America (PhRMA) has raised more than $100,000 to establish a new grant for blood cancer research. This Sunday, April 28, Team PhRMA will be participating in the inaugural Nike Women Half Marathon DC, benefiting the Leukemia & Lymphoma Society’s Team in Training program. 

Read more. 


PhRMA Elects New Member to Board of Directors

Washington, D.C. (April 22, 2013) — The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today the election of Orexigen Therapeutics President and CEO Michael A. Narachi to its Board of Directors.

Read more.


PhRMA Statement on Medicare Drug Savings Act of 2013 

WASHINGTON, D.C. (April 16, 2013) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett today issued the following statement: "Several members of Congress today echoed President Obama’s recycling of a flawed policy proposal: imposing mandatory government price controls in Medicare Part D, cleverly disguised as “rebates.”

Read more


Celgene's Robert J. Hugin Becomes PhRMA Board Chairman

San Diego, CA (April 12, 2013) — Robert J. Hugin, chairman and CEO of Celgene Corporation, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) today at the trade association’s annual meeting. Also elected were Ian C. Read, president and CEO of Pfizer Inc, as chairman-elect of the PhRMA Board of Directors, and Kenneth C. Frazier, Chairman, President and CEO of Merck & Co, Inc., as Board treasurer.

Read more.


America's Biopharmaceutical Companies' Commitment to Research Remains Strong Despite Challenges

Washington, D.C. (April 11, 2013) — Investment in research and development (R&D) by member companies of the Pharmaceutical Research and Manufacturers of America (PhRMA) remained strong at an estimated $48.5 billion in 2012, despite economic, scientific, and business challenges. These efforts are highlighted in PhRMA’s 2013 Biopharmaceutical Research Industry Profile released today.
 

PhRMA Statement on President’s 2014 Budget

WASHINGTON, D.C. (April 10, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today: “President Obama has pressed for innovation and biomedical research, job creation, and controlling health care costs and yet his 2014 budget again includes stale, previously rejected proposals that would undercut all of these efforts.
 

PhRMA Statement on India Supreme Court Decision on Glivec

WASHINGTON, D.C. (April 1, 2013)– Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani issued the following statement today.

“PhRMA is very disappointed with the Indian Supreme Court’s decision to deny a patent on Glivec. This decision marks yet another example of the deteriorating innovation environment in India.  Innovation is critical in meeting unmet needs of patients and is particularly relevant in the context of changing healthcare systems. In order to solve the real health challenges of India’s patients, it is critically important that India promote a policy environment that supports continued research and development of new medicines for the health of patients in India and worldwide. Protecting intellectual... 

Read more


 
New Orleans, LA (March 27, 2013) – Rx Response Director and PhRMA Associate Vice President for IT & Operations Erin Mullen, PhD., RPh, CEM, received the Outstanding Achievement Award for Preparedness at the National Hurricane Conference in New Orleans today.Mullen was recognized for her work in transforming Rx Response from a concept to a fully operational disaster preparedness and response program that encompasses the entire bio-pharmaceutical supply system, from manufacturers to distributors to dispensers.
 
Read more.

Over 8,200 Clinical Trials of Medicines Conducted by Texas Research Institutions Since 1999

WASHINGTON, D.C. (March 25, 2013) –  Working in collaboration with university medical schools and science centers, local hospitals and clinical research facilities, America’s biopharmaceutical companies have conducted more than 8,200 clinical trials of new medicines in Texas over the last 13 years, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). The report – “Research in Your Backyard: Pharmaceutical Clinical Trials in Texas” – was released today at a news conference with Sen. Bob Deuell, (R - Greenville), Rep. Jim Murphy, (R - Houston), Tom Kowalski, President, Texas Healthcare and Bioscience Institute and Dr. Curtis Triplitt, Asst. Professor, Diabetes/Medicine, the University of Texas Health Science Center at San Antonio Texas Diabetes Institute, in the Lt. Governor's Press Conference Room at the State Capitol.

Read more.


More Than 400 Innovative Medicines in Development For Top Chronic Diseases Affecting Older Americans

WASHINGTON, D.C. (March 20, 2013) – America’s biopharmaceutical research companies are developing 465 new medicines that target the 10 leading chronic conditions affecting seniors, according to a new report and overview released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Read more. 


Biologics Research Promises to Bolster Future of Medicine

WASHINGTON, D.C. (March 11, 2013) – America’s biopharmaceutical companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Read more


 

More On PhRMA — powered by PhRMApedia